Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon, Inc. (IMNN)
Price$1.45Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | — | — | — | — | — | — | — |
| Research & development | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M | $14.6M | $14.7M | $15.0M | $9.4M | $15.8M | $19.9M | $14.7M |
| Operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M | $19.0M | $21.1M | $21.6M | $19.0M | $21.1M | $21.3M | $25.2M | $15.9M | $22.1M | $25.0M | $19.6M |
| Operating income | −$14.7M | −$19.1M | −$21.0M | −$24.9M | −$21.0M | −$18.5M | −$20.6M | −$21.1M | −$18.5M | −$20.6M | −$20.8M | −$24.7M | −$15.4M | −$22.1M | −$23.0M | −$19.6M |
| Operating margin | — | — | — | −4,984.31% | −4,201.44% | −3,697.28% | −4,113.09% | −4,213.01% | −3,693.69% | — | — | — | — | — | — | — |
| EBITDA | −$14.4M | −$18.9M | −$20.8M | −$24.2M | −$20.3M | −$17.7M | −$19.8M | −$20.7M | −$17.9M | −$19.6M | −$20.4M | −$24.3M | −$15.1M | −$21.9M | −$22.8M | −$19.5M |
| EBITDA margin | — | — | — | −4,837.99% | −4,060.85% | −3,548.98% | −3,968.76% | −4,141.64% | −3,583.08% | — | — | — | — | — | — | — |
| Net income | −$14.5M | −$18.6M | −$19.5M | −$35.9M | −$20.8M | −$21.5M | −$16.9M | −$11.9M | −$20.4M | −$22.1M | −$22.5M | −$25.5M | −$8.3M | −$26.6M | −$23.2M | −$18.8M |
| Net profit margin | — | — | — | −7,179.65% | −4,153.85% | −4,296.71% | −3,370.31% | −2,376.67% | −4,080.44% | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$6.83 | -$16.94 | -$32.40 | -$75.45 | -$57.45 | -$151.20 | -$173.25 | -$153.00 | -$612.00 | -$2,675.25 | -$3,244.50 | -$4,347.00 | -$2,992.50 | -$10,836.00 | -$15,750.00 | -$1,064.00 |
| Diluted EPSper diluted share | -$6.83 | -$16.94 | -$32.40 | -$75.45 | -$57.45 | -$151.20 | -$173.25 | -$153.00 | -$612.00 | -$2,675.25 | -$3,244.50 | -$4,347.00 | -$2,992.50 | -$10,836.00 | -$15,750.00 | -$1,064.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 | Eylward SusanGeneral Counsel and Corp Sec | SellCommon Stock | 11.8K | $1.75 | $20.6K | 2.9K |
| Aug 20, 2024Form 4 | Braun Donald PDirector | BuyCommon Stock | 25.0K | $1.18 | $29.5K | 25.6K |
| Aug 15, 2024Form 4 | Lindborg StacyPresident and CEO | BuyImunon Common Stock | 25.0K | $0.98 | $24.5K | 264.2K |
| Aug 15, 2024Form 4 | Tardugno Michael HExecutive Chairman of Board | BuyImunon Common Stock | 25.0K | $1.03 | $25.8K | 353.3K |
Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...